At ASCO, researchers shared that in the persevERA trial, giredestrant didn't improve outcomes for first-line advanced breast cancer patients.

AstraZeneca Plc AZN on Tuesday reported updated Phase 3 SERENA-6 trial results showing that camizestrant combined with a CDK4 ...

To Roche, a phase 3 flop in first-line breast cancer does not erase the megablockbuster potential of its oral SERD drug ...

Further positive results from the Phase III SERENA-6 trial showed AstraZeneca's camizestrant plus a cyclin-dependent kinase (CDK) 4/6 inhibitor – palbociclib, ribociclib or abemaciclib – maintained ...

Gedatolisib plus fulvestrant and palbociclib (the “gedatolisib-triplet”) reduced the risk of disease progression or death by 50% vs. alpelisib plus fulvestrant (HR=0.50; 95% CI: 0.37–0.68; p0.0001).

Further positive results from the Phase III SERENA-6 trial showed AstraZeneca's camizestrant plus a cyclin-dependent kinase (CDK) 4/6 inhibitor ...

Gedatolisib triplet achieved mPFS 11.1 months vs 5.6 months with alpelisib/fulvestrant (HR 0.50; P<.0001), meeting the primary endpoint in a post-CDK4/6 inhibitor ...

The American Society of Clinical Oncology (ASCO) and Ryght AI are teaming up to identify research sites for an ASCO clinical ...

Analysis of samples from the NATALEE trial, presented at ASCO, revealed some response-linked gene-expression patterns, but ...

Abemaciclib (Verzenio) reduced the risk of progression or death by 62% compared with placebo in patients with advanced ...

Abemaciclib significantly prolonged PFS compared with placebo for patients with advanced dedifferentiated liposarcoma, ...